Business Context and Reporting Period
This Form 8-K filing by Coherus BioSciences, Inc. (referred to as Coherus Oncology, Inc. in metadata) covers the date of May 9, 2018. The report details a corporate governance change involving the Board of Directors.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to director compensation:
- Annual Cash Retainer: $45,000 for the newly appointed director.
- Equity Grant: Option to purchase 40,000 shares of common stock.
- Vesting Schedule: Substantially equal monthly installments over three years.
Material Changes
The Board of Directors increased its size from seven to eight members. Dr. Samuel Nussbaum was appointed as a Class II director to fill the new vacancy. His term expires at the 2019 annual meeting of stockholders.
Outlook, Risks, and Management Commentary
Management selected Dr. Nussbaum due to his significant experience in the health care policy industry. His background includes roles as Executive Vice President and Chief Medical Officer for Anthem, and extensive academic and clinical experience at Massachusetts General Hospital and Harvard Medical School. The filing notes the expectation of a standard indemnification agreement but does not disclose specific risks or contingencies related to this appointment.
Investor Verification Checklist
- Verify the closing price of Coherus common stock on May 9, 2018, to determine the exercise price of the 40,000 share option grant.
- Review the Company's Definitive Proxy Statement on Schedule 14A (filed April 13, 2018) for the full details of the Non-Employee Director Compensation policy.
- Confirm the terms of the standard form of indemnification agreement referenced in the filing.